Enhancement of E-cadherin expression and processing and driving of cancer cell metastasis by ARID1A deficiency
Jie Wang,Hai-Bo Yan,Qian Zhang,Wei-Yan Liu,Ying-Hua Jiang,Gang Peng,Fei-Zhen Wu,Xin Liu,Peng-Yuan Yang,Feng Liu
DOI: https://doi.org/10.1038/s41388-021-01930-2
IF: 8.756
2021-07-21
Oncogene
Abstract:The <i>ARID1A</i> gene, which encodes a subunit of the SWI/SNF chromatin remodeling complex, has been found to be frequently mutated in many human cancer types. However, the function and mechanism of <i>ARID1A</i> in cancer metastasis are still unclear. Here, we show that knockdown of <i>ARID1A</i> increases the ability of breast cancer cells to proliferate, migrate, invade, and metastasize in vivo. The <i>ARID1A</i>-related SWI/SNF complex binds to the second exon of <i>CDH1</i> and negatively modulates the expression of E-cadherin/<i>CDH1</i> by recruiting the transcriptional repressor ZEB2 to the <i>CDH1</i> promoter and excluding the presence of RNA polymerase II. The silencing of <i>CDH1</i> attenuated the migration, invasion, and metastasis of breast cancer cells in which <i>ARID1A</i> was silenced. <i>ARID1A</i> depletion increased the intracellular enzymatic processing of E-cadherin and the production of C-terminal fragment 2 (CTF2) of E-cadherin, which stabilized β-catenin by competing for binding to the phosphorylation and degradation complex of β-catenin. The matrix metalloproteinase inhibitor GM6001 inhibited the production of CTF2. In zebrafish and nude mice, <i>ARID1A</i> silencing or CTF2 overexpression activated β-catenin signaling and promoted migration/invasion and metastasis of cancer cells in vivo. The inhibitors GM6001, BB94, and ICG-001 suppressed the migration and invasion of cancer cells with <i>ARID1A</i>-deficiency. Our findings provide novel insights into the mechanism of <i>ARID1A</i> metastasis and offer a scientific basis for targeted therapy of <i>ARID1A</i>-deficient cancer cells.
oncology,genetics & heredity,biochemistry & molecular biology,cell biology